Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Buy
57
ABT Quote, Financials, Valuation and Earnings
Last price:
$124.50
Seasonality move
:
3.19%
Day range:
$120.85 - $127.76
52-week range:
$99.71 - $141.23
Dividend yield:
1.76%
P/E ratio:
16.61x
P/S ratio:
5.29x
P/B ratio:
4.62x
Volume:
10.2M
Avg. volume:
7.6M
1-year change:
12.98%
Market cap:
$220.3B
Revenue:
$42B
EPS (TTM):
$7.65
Analysts' Opinion
-
Consensus RatingAbbott Laboratories has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $136.47, Abbott Laboratories has an estimated upside of 7.43% from its current price of $127.04.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $111.34 representing 12.36% downside risk from its current price of $127.04.
Fair Value
-
According to the consensus of 20 analysts, Abbott Laboratories has 7.43% upside to fair value with a price target of $136.47 per share.
ABT vs. S&P 500
-
Over the past 5 trading days, Abbott Laboratories has underperformed the S&P 500 by -10.46% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Abbott Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Abbott Laboratories has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Abbott Laboratories reported revenues of $11B.
Earnings Growth
-
Abbott Laboratories has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Abbott Laboratories reported earnings per share of $5.27.
Enterprise value:
226.7B
EV / Invested capital:
--
Price / LTM sales:
5.29x
EV / EBIT:
29.94x
EV / Revenue:
5.40x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
35.70x
Price / Operating cash flow:
34.97x
Enterprise value / EBITDA:
21.01x
Gross Profit (TTM):
$23.2B
Return On Assets:
17.9%
Net Income Margin (TTM):
31.95%
Return On Equity:
32.63%
Return On Invested Capital:
24.06%
Operating Margin:
17.41%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $43.7B | $40.1B | $42B | $10.2B | $11B | |
| Gross Profit | $24.5B | $22.1B | $23.2B | $5.7B | $6B | |
| Operating Income | $8.4B | $6.5B | $6.8B | $1.8B | $1.9B | |
| EBITDA | $12.1B | $10.5B | $10.8B | $2.8B | $3B | |
| Diluted EPS | $3.91 | $3.26 | $7.65 | $0.91 | $5.27 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $20.4B | $24.2B | $25.2B | $22.7B | $23.7B | |
| Total Assets | $72.5B | $75.2B | $74.4B | $73.2B | $81.4B | |
| Current Liabilities | $11.9B | $13.1B | $15.5B | $13.8B | $14.2B | |
| Total Liabilities | $39.5B | $39.2B | $37.5B | $34.4B | $33.5B | |
| Total Equity | $33B | $36B | $36.9B | $38.8B | $47.9B | |
| Total Debt | $18.7B | $18.1B | $16.8B | $14.7B | $14.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.6B | $7.3B | $8.6B | $3B | $2.9B | |
| Cash From Investing | -$1.7B | -$3.1B | -$2.3B | -$824M | -$866M | |
| Cash From Financing | -$7.6B | -$7.1B | -$5.4B | -$2.1B | -$1.9B | |
| Free Cash Flow | $7.8B | $5.1B | $6.4B | $2.3B | $2.1B | |
ABT
Sector
Market Cap
$220.3B
$33.7M
Price % of 52-Week High
89.95%
40%
Dividend Yield
1.76%
0%
Shareholder Yield
2.75%
-0.91%
1-Year Price Total Return
12.99%
-46.85%
Beta (5-Year)
0.803
0.743
Dividend yield:
1.76%
Annualized payout:
$2.20
Payout ratio:
28.62%
Growth streak:
11 years
Technicals
8-day SMA
Sell
Level
$128.52
200-day SMA
Buy
Level
$116.99
Bollinger Bands (100)
Buy
Level
114.69 - 131.31
Chaikin Money Flow
Buy
Level
2B
20-day SMA
Sell
Level
$128.04
Relative Strength Index (RSI14)
Sell
Level
45.61
ADX Line
Sell
Level
24.04
Williams %R
Neutral
Level
-50.1139
50-day SMA
Sell
Level
$130.63
MACD (12, 26)
Sell
Level
-0.96
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
1.3B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2817)
Buy
CA Score
(Annual)
Level (0.455)
Sell
Beneish M-Score
(Annual)
Level (-2.0935)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-3.0498)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Stock Forecast FAQ
In the current month, ABT has received 13 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ABT average analyst price target in the past 3 months is $136.47.
-
Where Will Abbott Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Abbott Laboratories share price will rise to $136.47 per share over the next 12 months.
-
What Do Analysts Say About Abbott Laboratories?
Analysts are divided on their view about Abbott Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Abbott Laboratories is a Sell and believe this share price will drop from its current level to $111.34.
-
What Is Abbott Laboratories's Price Target?
The price target for Abbott Laboratories over the next 1-year time period is forecast to be $136.47 according to 20 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is ABT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Abbott Laboratories is a Buy. 13 of 20 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABT?
You can purchase shares of Abbott Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Abbott Laboratories shares.
-
What Is The Abbott Laboratories Share Price Today?
Abbott Laboratories was last trading at $124.50 per share. This represents the most recent stock quote for Abbott Laboratories. Yesterday, Abbott Laboratories closed at $127.04 per share.
-
How To Buy Abbott Laboratories Stock Online?
In order to purchase Abbott Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 15.35% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 12.66% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 13.3% over the past day.
